Quick-Med to present abstracts on antimicrobial technologies at Clinical Symposium

NewsGuard 100/100 Score

Quick-Med Technologies, Inc. (OTCBB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today its NIMBUS® and Stay Fresh™ antimicrobial technologies will be highlighted at the 2010 Clinical Symposium on Advances in Skin and Wound Care, to be held in Orlando, Florida from September 30 – October 3, 2010.

NIMBUS and Stay Fresh are part of Quick-Med's suite of technologies aimed at infection control and prevention. At the symposium, Quick-Med will present two abstracts on its recent studies of both technologies.

NIMBUS® Advanced Active, a new prototype wound dressing, will be featured in the first abstract entitled, "Improved Healing in Tissue Culture Model of Vesicant Injury Shown by High Feature Antimicrobial Dressing." Results of NIMBUS® Advanced Active demonstrated significant wound healing improvements in chemically injured human tissue.

Quick-Med's Stay Fresh textiles technology is the subject of the second abstract entitled, "Antifungal and Antibacterial Textiles to Interrupt Pathogen Transfer." Results support the efforts of Quick-Med Technologies to develop Stay Fresh textile treatments that provide durable and highly effective bacterial and fungal control, to help prevent Hospital Acquired Infections (HAIs).

"I am excited to present these abstracts on the unique technologies NIMBUS Advanced Active and Stay Fresh," said Dr. Bernd Liesenfeld, Senior Scientist of Quick-Med. "Derived from Quick-Med's FDA-approved NIMBUS technology, NIMBUS Advanced Active is shown to significantly enhance wound healing. It is the ultimate multi-functional dressing, with applicability for acute and chronic wounds."

Source:

: Quick-Med Technologies

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study finds interferon-γ release assays more effective than skin tests in predicting tuberculosis